We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by ENT Technologies Pty Ltd
I, Rowena Love, as a delegate of the Secretary to the Department of Health, on receipt of an application from ENT Technologies Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989 ( the Act), the restricted representation described in paragraph (A), for use in advertising the products identified in paragraph (B) to consumers.
-
- Suitable for asthma patients (the Suitability Statement); and
- Eze Allergy proudly supports the work of Asthma Australia. The Asthma Australia logo in this advertisement does not in any way constitute an endorsement of ENT Technologies or Eze Allergy.
-
- EZE ALLERGY azelastine hydrochloride 1 mg/mL nasal spray bottle (AUST R 310747)
Dated this 11th day of November 2021
Signed electronically
Rowena Love
Delegate of the Secretary to the Department of Health
Advertising and Compliance Education and Policy Section
Regulatory Compliance Branch